Sutro Biopharma Inc
NASDAQ:STRO
Intrinsic Value
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. [ Read More ]
The intrinsic value of one STRO stock under the Base Case scenario is 8.2 USD. Compared to the current market price of 3.77 USD, Sutro Biopharma Inc is Undervalued by 54%.
Valuation Backtest
Sutro Biopharma Inc
Run backtest to discover the historical profit from buying and selling STRO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Sutro Biopharma Inc
Current Assets | 421.5m |
Cash & Short-Term Investments | 375.6m |
Receivables | 36.1m |
Other Current Assets | 9.8m |
Non-Current Assets | 49.2m |
PP&E | 44.8m |
Other Non-Current Assets | 4.4m |
Current Liabilities | 93.7m |
Accounts Payable | 9.4m |
Accrued Liabilities | 59.6m |
Other Current Liabilities | 24.7m |
Non-Current Liabilities | 227.3m |
Other Non-Current Liabilities | 227.3m |
Earnings Waterfall
Sutro Biopharma Inc
Revenue
|
153.7m
USD
|
Operating Expenses
|
-243m
USD
|
Operating Income
|
-89.3m
USD
|
Other Expenses
|
-17.5m
USD
|
Net Income
|
-106.8m
USD
|
Free Cash Flow Analysis
Sutro Biopharma Inc
What is Free Cash Flow?
STRO Profitability Score
Profitability Due Diligence
Sutro Biopharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Sutro Biopharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
STRO Solvency Score
Solvency Due Diligence
Sutro Biopharma Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Sutro Biopharma Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STRO Price Targets Summary
Sutro Biopharma Inc
According to Wall Street analysts, the average 1-year price target for STRO is 13.15 USD with a low forecast of 8.08 USD and a high forecast of 21 USD.
Ownership
STRO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
STRO Price
Sutro Biopharma Inc
Average Annual Return | 5.06% |
Standard Deviation of Annual Returns | 53.57% |
Max Drawdown | -92% |
Market Capitalization | 290m USD |
Shares Outstanding | 76 920 704 |
Percentage of Shares Shorted | 3.91% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
Contact
IPO
Employees
Officers
The intrinsic value of one STRO stock under the Base Case scenario is 8.2 USD.
Compared to the current market price of 3.77 USD, Sutro Biopharma Inc is Undervalued by 54%.